SCHEMBL30250053

SCHEMBL30250053

Cc1ccc(-c2cccc(/C=C3\SC(=S)NC3=O)c2)cc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAT1 P18440 5/20 0.74
ADAMTS5 Q9UNA0 2/20 0.69
CISD1 Q9NZ45 2/20 0.62
GSK3B P49841 2/20 0.60
CA2 P00918 1/20 0.59
EPHX1 P07099 1/20 0.59
CRHBP P24387 1/20 0.57
CRHR2 Q13324 1/20 0.57
MMP3 P08254 1/20 0.57
MMP13 P45452 1/20 0.57
PIM1 P11309 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
RAB9A P51151 1/20 0.55
PIM2 Q9P1W9 1/20 0.54
POLB P06746 1/20 0.54
MYC P01106 1/20 0.53
MAX P61244 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18102890 0.89 NAT1 (0.76) NAT1ADAMTS5CISD1GSK3BCA2
SCHEMBL18102962 0.89 NAT1 (0.76) NAT1ADAMTS5CISD1GSK3BCA2
SCHEMBL19991267 0.89 NAT1 (0.76) NAT1ADAMTS5CISD1GSK3BCA2
SCHEMBL18103002 0.87 NAT1 (0.74) NAT1ADAMTS5CISD1CA2EPHX1
SCHEMBL8312114 0.86 ADAMTS5 (0.75) NAT1ADAMTS5CISD1MMP3MMP13
SCHEMBL7557614 0.85 NAT1 (1.00) NAT1ADAMTS5CISD1GSK3BCA2
SCHEMBL7557609 0.85 NAT1 (1.00) NAT1ADAMTS5CISD1GSK3BCA2
SCHEMBL18103005 0.83 NAT1 (0.85) NAT1ADAMTS5CISD1CA2EPHX1
SCHEMBL8167436 0.82 PIM1 (0.75) NAT1CISD1CA2EPHX1CRHBP
SCHEMBL8167434 0.82 PIM1 (0.75) NAT1CISD1CA2EPHX1CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023039170-A1 SELECTIVE TARGETING OF CD38 ACTIVITY AS AN IMMUNOSTIMULATORY AND ANTITUMOR STRATEGY MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2023-03-16 WO disclosed